In VitroSynergy andIn VivoActivity of Tigecycline-Ciprofloxacin Combination Therapy against Vibrio vulnificus Sepsis | Zendy

Seong Eun Kim | Zendy; Hee Kyung Kim | Zendy; SuMi Choi | Zendy; Yohan Yu | Zendy; Uh Jin Kim | Zendy; Kalifa Sanneh Darboe | Zendy; SeungJi Kang | Zendy; KyungHwa Park | Zendy; Gaeun Kang | Zendy; Young Ran Kim | Zendy; Joon Haeng Rhee | Zendy; SookIn Jung | Zendy; HeeChang Jang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In VitroSynergy andIn VivoActivity of Tigecycline-Ciprofloxacin Combination Therapy against Vibrio vulnificus Sepsis

Author(s) -

Seong Eun Kim,

Hee Kyung Kim,

SuMi Choi,

Yohan Yu,

Uh Jin Kim,

Kalifa Sanneh Darboe,

SeungJi Kang,

KyungHwa Park,

Gaeun Kang,

Young Ran Kim,

Joon Haeng Rhee,

SookIn Jung,

HeeChang Jang

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00310-19

Subject(s) - vibrio vulnificus , tigecycline , ciprofloxacin , minocycline , sepsis , microbiology and biotechnology , antibiotics , medicine , in vivo , pharmacology , cefotaxime , biology , bacteria , genetics

The mortality rate associated withVibrio vulnificus sepsis remains high. Anin vitro time-kill assay revealed synergism between tigecycline and ciprofloxacin. The survival rate was significantly higher in mice treated with tigecycline plus ciprofloxacin than in mice treated with cefotaxime plus minocycline. Thus, combination treatment with tigecycline-ciprofloxacin may be an effective novel antibiotic regimen forV. vulnificus sepsis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research